Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.

Following up on our previous post about Gene Therapies, we are sharing data on Genetic Medicines in development - pipelines, targets, dates

We've been keeping Eyes On the Gene Therapy area - and thought we would post some general information about the area ...

The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and

Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.

While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...

We found ourselves looking closer at the disease, the history of weight loss medications, and the potential impact of effective weight manag

This week we had Eyes On the upcoming IRA Drug pricing negotiations - here's some of the news and views we saw.

We have Eyes on Pharma Conferences this week. Don't forget to check PharmaTell Studio for the latests Planners, Insights, and Key Takes.

The MedTech sector seemed to take the brunt of the 2022 market decline but looking to forward there may be light at the end of the tunnel.

We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...

I've got Eyes On the Review / Preview Articles for the Healthcare Industry. It's interesting to see a snapshot of 2022 and some predictions

After all the quarterly results reporting, we've had eyes on product approvals, resubmissions, and a withdrawal.

This week PharmaTell had Eyes On: Heartburn – the kind caused by the upcoming Zantac litigation & resulting market jitters.

This week we had Eyes On Amazon & One Medical – as did many of you, I am sure. We saw the news and, of course, had a variety of thoughts...

We are excited to announce PharmaTech Outlook selected us as one of the Top 10 Pharma Marketing Services Companies in Europe – 2022!

The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.

As with most of you I'm sure - this week the PharmaTell Team had Eyes on ASCO + positive data for postpartum depression patients.